Plasmodium falciparum Carriage in central and northern Mali amid Seasonal Malaria Chemoprevention implementation

Short title: *Plasmodium falciparum* Carriage in Mali

Betty Kazanga[1*], Mady Cissoko[2], Abdoulaye Katile[1,3], El Bahdja Boudoua[1], Eva Legendre[1,4], Bourama Kamate[3], Moussa Bamba Kanoute[3], Paul Kone[5] Abdoulaye Djiguiba[3], Ousmane dit Abel Poudiougo[3], Moulaye Coulibaly[3], Amatigue Zeguime[3], Antoine Claessens[6], Coralie L'Ollivier[7,8], Maissane Mehadji[7,8], Stéphane Ranque[7,8], Marc-Karim Bendiane[9,10], El-Hadj Konco Ciré Ba[11], Abdoulaye Djimde[3], Jean Gaudart[12], Issaka Sagara[3], Jordi Landier[1].

[1] Aix Marseille Univ, IRD, INSERM, SESSTIM, ISSPAM, Marseille, France.

[2] National Malaria Control Program, Ministry of Health and Social Development, Bamako, Mali.

[3] Malaria Research and Training Center, University of sciences, Techniques and Technologies of Bamako, Bamako, Mali.

[4] Hôpital Européen, Marseille France.

[5] District hospital (CSREF) of Dire, Region of Tombouctou, Mali

[6] LPHI, CNRS, INSERM, University of Montpellier, Montpellier, France.

[7] Aix-Marseille Univ., AP-HM, SSA, RITMES, 13005 Marseille, France.

[8] IHU Méditerranée Infection, 13005 Marseille, France.

[9] Service de médecine interne, gériatrie et thérapeutique, Assistance publique hôpitaux de Marseille (AP-HM), Marseille, France

[10] ADES UMR 7268, AMU, CNRS, EFS, Marseille, France

[11] Aix Marseille Univ, IRD, MINES, IRD-UCAD International Campus, Dakar, Senegal.

[12] Aix Marseille Univ, IRD, INSERM, SESSTIM, ISSPAM, AP-HM, Hop. La Timone, BioSTIC, Marseille, France.

*Corresponding author

Email: b.kazanga@gmail.com

Abstract

Introduction: Seasonal malaria chemoprevention (SMC) reduces malaria incidence in children under five in Mali, yet transmission persists likely due to chronic low-density *Plasmodium falciparum* infections which are often asymptomatic and undetectable by routine field diagnostics. This study characterises the *P. falciparum* reservoir in two distinct Malian settings with routine SMC.

Methods: We conducted a cohort study (2021-2022) of 670 participants from four Malian villages (two in Kati, two in Dire). During four survey visits (T0-T3), infection was detected using rapid diagnostic tests (RDTs) and quantitative PCR (qPCR). Weekly clinical malaria incidence, *P. falciparum* PCR prevalence, parasite density and multiplicity of infection (eMOI) were calculated. We evaluated factors associated with *P. falciparum* carriage using multivariable regression.

Results: In Kati, incidence followed rainfall, peaking in 20–24-year-olds (T1–T2), while in Dire it peaked during Niger River flooding, mainly in 5–24-year-olds (T2-T3). qPCR prevalence reached 33.3% in Kati and 60% in Dire, RDT sensitivity was low, over half of the infections were <100 parasites/µL and eMOI was higher in Kati peaking in 10–25 year-olds.

Discussion Our findings show that asymptomatic and subpatent infections sustain transmission in Mali with 5–24 years olds as major parasite reservoirs due to their high infection prevalence, parasite densities, and multiplicity. Predominance of polyclonal infections indicates ongoing exposure despite reduced clinical incidence.

Conclusion: SMC has shifted malaria incidence from under-fives to older age groups now sustaining transmission. Targeting asymptomatic carriers beyond SMC coverage is essential to further reduce transmission and advance elimination in seasonal settings.

Keywords: Malaria, *Plasmodium falciparum*, Asymptomatic carriage, Seasonal Malaria Chemoprevention

Introduction

In 2023, Mali remained among the 11 nations with the highest *Plasmodium falciparum* malaria burden, reporting an estimated 8.2 million cases (3.1% global cases) and 14,200 deaths (2.4% global deaths) [1]. Clinical malaria incidence peaks during the rainy season (July-November), prompting intensified control efforts including Seasonal Malaria Chemoprevention (SMC).

Since 2012, SMC in Mali consists of monthly administration of sulfadoxine-pyrimethamine plus amodiaquine (SP-AQ) to children aged 3–59 months during the rainy season with 3 to 5 cycles annually depending on the local transmission intensity. In 2021, coverage reached 83-86% per cycle; 79% completed four cycles meeting national and WHO coverage targets [2,3]. SMC protects for 28 reducing clinical malaria incidence by 75%–90% and parasitemia by 62% in targeted children [4,5].

While SMC offers strong protection in the target age group, its broader impact on transmission remains poorly characterised. A 2021 Gambian study conducted following the extension of SMC to children up to 10 years (previously up to 5 years), showed that increased SMC coverage was associated with a reduced risk of infection for non-eligible members of the same household [6]. However, sustained transmission amid SMC, including in Eastern Senegal, where children are eligible up to 10 years of age, suggests that SMC, vector control and improved access to early diagnostic and treatment are unable to reduce transmission below certain levels [5,7]. One key aspect of malaria persistence, unaddressed by current control interventions, is chronic *P. falciparum* infections, generally subclinical or even asymptomatic, and often at low parasite densities, undetectable by routine diagnostic tools. Pre-SMC studies in the Sahel found these in all ages. Studies performed in the SMC context show a lower prevalence in SMC-eligible groups, but persistence of infections in SMC-ineligible age-groups [7,8]. Asymptomatic *P. falciparum* infections maintain dry season transmission and resurgence with rain[9,10].

In Mali, approximately 11% of SMC-eligible children carry asymptomatic infections before the SMC campaign, increasing clinical risk within four weeks after receiving SMC [11]. Persistent reservoirs sustain the parasite pool between seasons and hinder elimination. Their persistence is shaped by naturally acquired immunity, developed through repeated exposure, which modulates parasite density, clinical presentation, and parasite gene expression patterns such as *var* gene profiles [10,12].

To support adaptive control strategies and address persisting malaria transmission, understanding the structure and seasonal dynamics of the reservoir, in terms of human hosts and parasite population is necessary. Multiplicity of infection (MOI) adds insights into the number of distinct parasite lineages within individuals and overall transmission intensity[13,14]. This study characterises the reservoir in two distinct epidemiological settings in Mali, where SMC is routinely implemented.

Methods

Study design and setting

We conducted a prospective cohort study in four villages of Central and Northern Mali. In Central Mali, the study was carried out in villages of Safo (4000 inhabitants) and Torodo (2000 inhabitants)located in Kati health district, approximately 15km northwest of Bamako, where malaria transmission is highly seasonal, peaking between June and December[15,16]. In Northern Mali, the study took place in the Dire health district, in Bourem Sidi Amar (2176 inhabitants) and Koigour (746 inhabitants) villages, located in the Niger River inner delta, which floods from August to February. This results in a bimodal malaria transmission pattern, with peaks in August–September and again in December–February/March [17]. In 2021, SMC (Four rounds) ran in Kati but was cancelled in Dire due to SMC drug shortages. Kati's cohort was close; Dire had new participants at the first follow-up survey (T1).

Participant enrollment and ethics

A household census conducted in all four villages identified then randomly selected households. All present at baseline were enrolled. In Dire new household members were included during follow-up. First, verbal consent was sought from the head of household, then written informed consent was obtained for all participants aged 18 and older. A parent or legal guardian provided consent for participants <18 years, and participants aged 12-17 years provided a written assent. Participants who were unable to read or write were assisted by a literate witness. The study protocol was approved by the Mali Ethics Committee (protocol No. 2020/297/CE/FMOS/ FAPH).

Follow-up and data collection

Over a year, four surveys were conducted to detect asymptomatic *P. falciparum* infections and administer structured questionnaires: T0 (May- June 2021), T1 (late July in Kati after the first round of SMC; mid-September in Dire), T2 (mid-December 2021), T3 (end March 2022). Weekly household visits tracked mobility, and health facilities and Community Health Workers (CHW) captured clinical cases.

Survey visits

At survey visits, tablet-based questionnaires captured sociodemographics, risk factors for *P. falciparum* infection (bed net use, infection, treatment, nighttime outdoor activities, and travel). Finger-prick blood was tested using a rapid diagnostic test (RDT; SD Bioline Malaria Ag Pf, Abbott Diagnostics Korea, Gyeonggi-do, South Korea), a thick smear for microscopy and a dried blood spot for polymerase chain reaction (PCR). RDT-positive participants in Dire were treated regardless of symptoms; in Kati only symptomatic participants were treated according to national malaria treatment guidelines.

Follow-up between surveys

Between surveys, CHWs recorded all RDT-confirmed malaria cases among cohort participants in a clinical registry for digitized using REDCap; weekly mobility was captured by brief questionnaires.

Laboratory analyses

Parasite density was estimated by quantitative PCR (qPCR) targeting the multicopy *P. falciparum* var acidic terminal sequence (*varATS*) gene as parasites per microliter of blood. Detailed methods, including sample processing, DNA extraction, and assay conditions, were described previously[7].

PCR-positive samples were genotyped by SpotMalaria consortium at Wellcome Sanger Institute using amplicon-based sequencing method[18]. The output consisted of 101 bi-allelic SNPs located on the 14 chromosomes and concatenated into a 'molecular barcode', plus six markers of resistance to antimalarials (*aat1* S528L, *crt* K76T, *dhfr* S108N, *dhps* A437G, *kelch13* C580Y and *mdr1* N86Y). Genetic barcode SNPs had been picked for their variable allele frequencies within the *P. falciparum* population.

Data analysis and statistical methods

All analysis was conducted using R software version 4.5.1 [19] and stratified by site.

Malaria incidence and prevalence

In this study, clinical cases referred to RDT-confirmed infections between visits, and asymptomatic *P. falciparum* infections referred to qPCR-positive infections detected at survey visits.

The cumulative incidence between survey visits was calculated as the number of clinical cases divided by the total person-time at risk. Weekly incidence was calculated by dividing the number of RDT-

confirmed cases each week by the number of participants under follow-up that week. In Dire, where weekly mobility data were unavailable, follow-up time was estimated based on survey visit attendance: 100% for participants who were present at two consecutive visits, 50% for those present at one visit, and no follow-up time for those not present at any survey visit.

P. falciparum prevalence was defined as the proportion of qPCR-positive individuals at a survey visit. Prevalence by visit and age group was calculated as the number of positives divided by the total tested in each group. To estimate 95% confidence intervals of prevalence estimates, we used the `{survey}` package in R, accounting for a simple cluster sampling design with varying cluster sizes [20,21].

Parasitemia analysis

We evaluated parasite density patterns among infected individuals and assessed RDT sensitivity in the cohort. Parasitemia was categorised into five ranges: <3, 3–10, 10–100, 100–1000, and >1000 parasites/μL. For each age group and survey, we calculated the proportion of samples within each density range and the corresponding RDT sensitivity.

Multiplicity of infection

Multiplicity of Infection (MOI), also known as complexity of infection (COI), is a genetic metric that quantifies the number of distinct *P. falciparum* strains simultaneously infecting a single host.

Using the barcodes obtained from MalariaGEN Spot Malaria, the effective multiplicity of infection (eMOI) was estimated with the Bayesian MOIRE R package, which adjusts the conventional MOI to account for relatedness among parasite clones within each infection. This approach accommodates situations in which parasites within a host may be genetically related rather than entirely independent[22].

eMOI is defined as:

$$eMOI = MOI \times (1 - r_w) + 1$$

Where r_w is the average genomic relatedness among clones within a host.

Infections with eMOI > 1.1 were considered polyclonal (multiple parasite genotypes). Those with eMOI ≤ 1.1 were classified as monoclonal (single parasite genotype), which is a practical threshold supported by several studies[13,23]. An eMOI of 1.5 can be interpreted as a mixed infection where most parasites share one genotype, whereas an eMOI of 2 could be two unrelated parasite lineages, or three parasite lineages, of which two are related.

Factors associated with *Plasmodium falciparum* carriage

We defined *P. falciparum* carriage as qPCR-positive infection at surveys. We analysed factors associated with carriage using generalised additive mixed logistic regression models (GAMMs) in the {mgcv} package[24]. Explanatory variables included age, sex, participation in SMC, correct bed net use (reported daily use without body parts outside the net), nighttime outdoor activities, and mobility. Previous clinical malaria and carriage at the preceding survey visit were also included to account for persistence or recurrence of infections. Nighttime activities and mobility were summarised into profiles using principal component analysis (PCA) followed by hierarchical clustering (HCPC) [25].

Three models were fitted. The first examined age and sex across all four surveys, with random intercepts for village, household, and individual to account for clustering and repeated measures; penalised splines modelled potential non-linear effects of age. The second tested associations with prior clinical malaria (T1–T2) and carriage at the previous survey visit (T1). The third, also at T2 focused on behavioural factors at T2, the period of highest prevalence, to maximise power for detecting risk factors. The second and third models included random intercepts for village and household only.

Results

Participants inclusion and follow-up

670 participants enrolled: 314 (47%) from 45 Kati households; 356 (53%) from 53 Dire households (Supplementary Figure 1). In Kati, 63 participants (20%) and 5 households (11%) were lost to follow-up; 251 (80%) completed four visits. In Dire, 66 participants (18.5%) and 1 household (2%) were lost, 28 new participants joined during T1 and 243 (68%) completed all four visits. Dried blood spot (DBS) collection rates remained high in both sites (>94% in Kati and >80% in Dire).

Participants description

The mean household size was approximately five participants in both sites. 53.8% of participants were under 15 years in Kati and 48% in Dire. 50.6% were females in Kati and 55.2% in Dire (Table 1).

At baseline survey (2020 wet season), reported SMC participation among eligible children (<5 years) was 82% in Kati and 97% in Dire (Table 1). Post SMC (2021, T2), reported participation was 77% (44/57) in Kati and not implemented in Dire (Table 1). Reported correct bed net use ranged from 10% to 31.8% in Kati and 37.8% to 51.7% in Dire (Table 1). Household nighttime activities were more common than work/vigil, except at T2 in Dire. Most reported no travel (41.6%–94.8%); among those who did, trips lasting more than one week were more common(Table 1).

Table 1: Socio-demographic characteristics and Health behaviour of cohort participants linked to malaria. N(%)

	A. Kati			
	T0	**T1**	**T2**	**T3**
	(n=314)	**(n= 292)**	**(n=278)**	**(n=251)**
Village				
Safo	154 (49)	142 (48.6)	138 (49.6)	128 (51)
Torodo	160 (51)	150 (51.4)	140 (40.4)	123 (49)
Sex				
Male	155 (49.4)	145 (49.7)	139 (50)	125 (49.8)
Female	159 (50.6)	147 (50.3)	139 (50)	126 (50.2)
Age (yrs)				
<5	55 (17.5)	53 (18.2)	50 (18)	46 (18.3)
5-9	46 (14.6)	44 (15.1)	44 (15.8)	43 (17.1)
10-14	68 (21.7)	64 (21.9)	63 (22.7)	58 (23.1)
15-19	27 (8.6)	23 (7.9)	20 (7.2)	15 (6)
20-24	14 (4.5)	12 (4.1)	12 (4.3)	10 (4)
25-34	32 (10.2)	31 (10.6)	29 (10.4)	26(10.4)
35-49	41 (13.1)	38 (13)	35 (12.6)	33 (13.1)
≥50	31 (9.9)	27 (9.2)	25 (9.0	20 (8)
Bednet use				
Correct use	65 (20.7)	93 (31.8)	63 (22.7)	26 (10)
Incorrect use	243 (77.4)	194 (66.4)	213 (76.6)	219 (87.3)
Missing data	6 (1.9)	5 (1.7)	2 (0.7)	6 (2.4)
SMC during the previous rainy season*				
Eligible, yes	60 (19.1)	58 (19.9)	44 (15.8)	41 (16.3)
Eligible, no	13 (4.1)	13 (4.5)	13 (4.7)	11 (4.4)
Not eligible (>5 yrs)	241 (76.8)	221 (75.7)	221 (79.5)	199 (79.3)
Reported outdoor nighttime activity profile				
Often (House activity)	62 (19.7)	161 (55.1)	63 (22.7)	54 (21.5)

	T0	T1	T2	T3
Often (work & vigil)	37 (11.8)	120 (41.1)	24 (8.6)	42 (16.7)
Rarely	215 (68.5)	11 (3.8)	191 (68.7)	155 (61.8)
Reported mobility profile				
No travel	199 (63.4)	246 (90.4)	205 (73.7)	119 (47.4)
<1 week within region	24 (7.6)	9 (3.1)	16 (5.8)	22 (8.8)
>1 week within country	85 (27.1)	14 (4.8)	55 (19.8)	103 (41)
Unknown	6 (1.9)	5 (1.7)	2 (0.7)	7 (2.8)

		B. Dire		
	T0	**T1**	**T2**	**T3**
	(n=328)	**(n=315)**	**(n=293)**	**(n=290)**
Village				
Koigour	162 (49.4)	148 (47)	144 (49.1)	141 (48.9)
Bourem Sidi Amar	166 (50.6)	167 (53)	169 (50.9)	159 (51.4)
Sex				
Male	147(44.8)	140 (44.4)	128 (43.7)	119 (41)
Female	181 (55.2)	175 (55.6)	165 (56.3)	171 (59)
Age (yrs)				
<5	63 (19.2)	58 (18.4)	55 (18.8)	54 (18.6)
5-9	50 (15.2)	50 (15.9)	45 (15.4)	47 (16.2)
10-14	45 (13.7)	47 (14.9)	43 (14.7)	44 (15.2)
15-19	30 (9.1)	26 (8.3)	23 (7.8)	25 (8.6)
20-24	24 (7.3)	21 (6.7)	20 (6.8)	20 (6.9)
25-34	40 (12.2)	36 (11.4)	35 (11.9)	32 (11)
35-49	38 (11.6)	37 (11.7)	36 (12.3)	32 (11)
≥50	38 (11.6)	40 (12.7)	36 (12.3)	36 (12.4)
Bednet use				
Correct use	124 (37.8)	152 (48.3)	139 (47.4)	150 (51.7)
Incorrect use	181 (55.2)	162 (51.4)	149 (50.9)	138 (47.6)
Missing data	23 (7)	1 (0.3)	5 (1.7)	2 (0.7)

SMC during the previous rainy season*				
Eligible, yes	71 (21.6)	67 (21.3)	0 (0)*	0 (0)*
Eligible, no	2 (0.6)	1 (0.3)	48 (16.4)*	44 (15.2)*
Not eligible (>5 yrs)	252 (76.8	244 (77.5)	243 (82.9)	229 (82.4)
Missing	3 (0.9)	3 (1)	2 (0.7)	7 (2.4)
Reported outdoor nighttime activity profile				
Often (House activity)	179 (54.6)	111 (35.2)	52 (17.7)	46 (15.9)
Often (work & vigil)	26 (7.9)	103 (32.7)	77 (26.3)	20 (6.9)
Rarely	123 (37.5)	101 (31.1)	164 (56)	224 (77.2)
Reported mobility profile				
No travel	232 (70.7)	131 (41.6)	161 (54.9)	275 (94.8)
<1 week within region	36 (11)	33 (10.5)	12 (4.1)	1 (0.3)
>1 week within country	37 (11.3)	149 (47.3)	115 (39.4)	13 (4.5)
Unknown	23 (7)	2 (0.6)	5 (1.9)	1 (0.3)

*No Seasonal Malaria Chemoprevention (SMC) campaign in Dire in the 2021 rainy season

Clinical malaria incidence

During follow-up, 71 clinical malaria cases were reported among cohort participants in Kati and 100 in Dire (Supplementary Table 1). In Kati, during the 2021 rainy season during the 2021 rainy season (late May- late October), a total of 894mm of rainfall was recorded and incidence began to rise in July 2021, coinciding with rainfall. Incidence declined with SMC rounds then rebounded in subsequent weeks (Fig. 1). Peak wet season (T1–T2) incidence was among ages 20–24 years (Supplementary Figure 2).

In Dire, during the 2021 rainy season (late June to early October) a total of 181mm of rainfall was recorded and incidence rose during the Niger river flooding (Fig. 1). Ages 5–24 years had the highest

incidence during the peak period (T2–T3, Supplementary Figure 2). The T2 survey coincided with the start of the high-transmission period in one Dire village but not the other (Supplementary Figure 3).

Fig 1. Weekly clinical malaria incidence (per 1,000 person-weeks), cumulative rainfall, and flooded terrain during the one-year cohort follow-up (2021–2022) in Kati (A) and Dire (B).

Vertical dashed lines mark the timing of the four Seasonal Malaria Chemoprevention (SMC) rounds in Kati. No SMC was done in Dire in 2021. Arrows indicate the timing of malaria prevalence surveys, and shaded boxes highlight the survey and prevalence(%).

P. falciparum prevalence

In Kati, peak qPCR prevalence (33.3%) was at the end of the wet season (T2, Figs. 1A,2A). Ages 10–24 years old had the highest prevalence (>40%) during the wet season (T2, Fig 3A). During dry low-transmission (T0, T3) highest prevalence was among 15-19 year olds (Fig. 3A).

In Dire, prevalence ranged from 60% (T0, T2) to 19% (T1) and 29% (T3) (Figs. 1B, 2B). Children <5 years had the lowest prevalence at T0 and T1, but without SMC levels were similar to other age groups at T2 and T3 (Fig. 3B).

RDT Sensitivity compared with qPCR ranged from 6–28% in Kati and 21–32% in Dire (Supplementary Table 2). Subpatent infections (i.e. qPCR-positive, RDT-negative) were more frequent in participants older than 20 years (Fig. 3)

Fig 2. *P. falciparum* **prevalence by quantitative Polymerase Chain Reaction (qPCR) and Rapid Diagnostic tests (RDT) among qPCR-positive participants during the four cross-sectional surveys in Kati (A) and Dire (B)**. **Bars represent 95% confidence intervals.**

Fig 3. *P. falciparum* **prevalence by quantitative Polymerase Chain Reaction (qPCR) and Rapid Diagnostic tests (RDT) among qPCR-positive participants during the four surveys in Kati (A) and Dire (B) by age groups.**

P. falciparum parasitaemia

Over 50% of infections had parasite densities below 100 parasites/μL; at T3 in Kati, all infections were below this. In Kati, median densities remained below 100 p/μL across all groups, with slightly higher median in the 10–19 age group at T2 (Supplementary Figure 3A) but not statistically significant at any visit (Kruskal–Wallis test, *p* > 0.05) (Supplementary Table 3). In Dire, median densities exceeded 100 p/μL at T0 (5–14 year olds), T2 (15–19 year olds) and T3 (5-9 year olds) (Supplementary Figure 3B), statistically significant at T0 (*p* = 0.0006) and T3 (*p* = 0.0391) (Supplementary Table 3).

Fig 4. *P. falciparum* **parasitemia during the four surveys in quantitative Polymerase Chain Reaction (qPCR) samples during the four cross-sectional surveys in Kati (A) and Dire (B).**

Multiplicity of infection

We obtained 300 genetic barcodes: 92 (Kati) and 208 (Dire). The proportion of polyclonal infections was slightly higher in Kati (71.7%) than in Dire (66.8%). Median eMOI was higher in Kati (1.37) than in Dire (1.25) (Fig. 5), indicating a predominance of polyclonal infections in both sites, with slightly more complex infections in Kati. The difference across age groups was not statistically significant in both sites (Kruskal–Wallis test, *p* > 0.05).

Fig 5. Distribution of effective Multiplicity Of Infection (eMOI) among Plasmodium falciparum quantitative Polymerase Chain Reaction (qPCR) positive survey participants in Kati (A) and Dire (B) and distribution across age groups by each site. The red dotted line indicates eMOI = 1.1, threshold used to classify polyclonal infections.

Median eMOI values remained above the polyclonal threshold for all age groups, indicating a predominance of polyclonal infections, except Kati 20-24 year group (Fig. 5). Children under 5 years had eMOI similar to older age groups. In Kati, the median eMOI was highest in 10–19-year-olds, while in Dire, eMOI peaked in the 20–24-year-olds. Overall, these patterns indicate more complex infections in under-5s and 10-24 year olds.

Factors associated with *P. falciparum* carriage

In Kati, odds of infection increased from dry season (T0) to end of wet season (T2, OR = 2.43, 95% CI: 1.49–3.96), then dropped by T3 (OR = 0.13, 95% CI: 0.06–0.29, Table 2). In Dire were similar T0 md T2 , lower and T1 (OR = 0.10) and at T3 (OR = 0.23, Table 2). There was no sex association at either site. Age-patterns varied by site and survey (Supplementary Figures 4–5). In Kati, age effects were most evident at T2 and T3, where children under 5 years had lower odds of infection (eg OR = 0.57, 95% CI: 0.35–0.94 T2), with risk increasing steadily with age (Supplementary Figure 4). In Dire, non-linear associations were observed at T0 and T1, with significantly lower odds among children under 5 years (eg OR = 0.70, 95% CI: 0.50–0.97 at age 5 in T0), and a peak in 10–19 years olds (e.g., OR = 1.64, 95% CI: 1.07–2.50 at age 19 in T0) (Supplementary Figure 5).

At T2 (Kati), non-SMC eligible participants had much higher odds of infection than eligible children who received SMC (OR 16.29, 95% CI 3.32–79.79, p = 0.0006; Supplementary Table 4). In Dire, travelling more than 1 week within the country lowered odds of infection than non-travellers (OR 0.38, 95% CI 0.18–0.80, p = 0.010). No link to bed net use or outdoor night activity at either site (Supplementary Table 4)

Clinical malaria (RDT between T1- T2) did not predict infection at T2 (Table 2). In Kati, prior qPCR positivity (T1) was strongly linked to infection at T2 (OR = 5.22, 95% CI: 2.14–12.75, *p* = 0.0003) but not in Dire.

Table 2: Odds Ratios (OR) estimates and 95% Confidence Intervals (CI) based on generalised additive Mixed logistic regression models

	A. KATI				B. DIRE			
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis	
	OR [95 CI]	*p*	OR [95 CI]	*p*	OR [95 CI]	*p*	OR [95 CI]	*p*
Model 1: Sociodemographic factors and *P. falciparum* infection detected by qPCR across four cross-sectional surveys (T0-T3)								
Visit								
T0	Ref.	1			Ref.	1		
T1	1.27 [0.79, 2.05]	0.3226	1.32 [0.81, 2.15]	0.2580	0.12 [0.08, 0.18]	0.0000	0.10 [0.07, 0.16]	0.0000
T2	2.41 [1.51, 3.86]	0.0002	2.43 [1.49, 3.96]	0.0004	0.98 [0.68, 1.40]	0.8907	0.98 [0.68, 1.41]	0.9048
T3	0.16 [0.08, 0.32]	0.0000	0.13 [0.06, 0.29]	0.0000	0.23 [0.16, 0.34]	0.0000	0.23 [0.16, 0.34]	0.0000
Sex								
Male	Ref.	1			Ref.	1		
Female	1.14 [0.64, 2.02]	0.6610	1.07 [0.59, 1.93]	0.8278	0.85 [0.64, 1.12]	0.2486	0.77 [0.58, 1.03]	0.0753
Model 2: Previous *P. falciparum* infection history and *P. falciparum* infection detected by qPCR at T2 survey								
Clinical malaria (RDT+) between T1-T2								
No	Ref.							
Yes	0.5 [0.19, 1.26]	0.1417	0.56 [0.21, 1.51]	0.2552	3.27 [0.33, 31.88]	0.3084	3.29 [0.34, 32.14]	0.3066
***P. falciparum* infection (qPCR+) during T1**								
No	Ref							
Yes	5.43 [2.23, 13.21]	0.0002	5.22 [2.14, 12.75]	0.0003	1.04 [0.37, 2.92]	0.9359	1.09 [0.39, 3.02]	0.8745

Discussion

This study demonstrates that *P. falciparum* infections are widespread in Mali and persist across age groups and seasons. Three main groups emerged: under-5s well protected with SMC but quickly exposed otherwise; children and youth (5–24 years), with the highest prevalence and parasite densities; and adults over 25, frequently infected at lower densities. Most Infections are undetected by RDTs and less likely to be treated, as they frequently cause little to no symptoms thus contributing to the transmission reservoir. Genetic analysis showed polyclonal infections were highest in adolescents and young adults, but still elevated in under-fives (SMC eligible), indicating that age groups beyond current SMC coverage also carry complex infections and contribute substantially to the parasite reservoir.

Transmission dynamics differed sharply between sites. Kati follows a typical rainfall-driven Sahelian profile, with low-density infections after rains. This is consistent with earlier analyses showing strong spatio-temporal variability of incidence linked to rainfall, river flow, and land use, with hotspots persisting even during the dry season[16]. The low clinical incidence suggests strong immunity. Dire patterns were dominated by rainfall and Niger River flooding, plus irrigated agriculture causing a January-March high transmission season [17,26].

Although Kati receives more rainfall, prevalence was consistently higher in Dire. Combined with higher parasite densities and lower eMOI compared to Kati, this suggests lower population immunity. This is consistent with the intensification of malaria transmission after the development of irrigated agriculture, and a population historically less exposed. The absence of SMC in Dire reinforced infections in children <5 during high transmission (T2). A cohort effect may be visible related to (i) the treatment of RDT-positive cases during surveys and (ii) improved access to treatment of clinical malaria for cohort participants, which may have contributed to lower prevalence in T1 and T3 surveys. These observations

complement previous studies showing Dire's bimodal transmission patterns driven by rainfall and flooding[17], with our cohort adding that during the flood-driven peak, asymptomatic infections are widespread across all ages, with reinfections dominating in the absence of SMC

The high polyclonal infections imply ongoing exposure to diverse parasite strains, even among asymptomatic carriers, explaining sustained transmission despite lower clinical incidence. Median eMOI of 1.37 in Kati and 1.25 in Dire indicates most infections are biclonal, with one dominant and one minor clone. These intermediate values suggest cotransmission rather than is the main source of polyclonality consistent with limited transmission diversity in these settings.

Population analyses in Kati show that SMC reduces community-level incidence [27]. Our cohort confirms protection for under-5s. Our results also show that those aged 10 to 24 had the highest wet season prevalence (T2), but also the highest parasite densities and multiplicity of infection. These results complement findings from Senegal, where SMC extends to age 10 years, SMC-eligible children have the lowest prevalence, while adolescents and young adults aged 15-24 years carried the greatest burden[7]. Our results suggest that those who receive SMC from infancy become key contributors to the reservoir after 5 years with high prevalence but also as individually good hosts (highest densities and eMOI). In Senegal, children immediately older than the SMC eligibility threshold presented the highest clinical malaria incidence not seen here. Mali with SMC stopping at age 5, youths and young adults already accounted for a large share of infections despite earlier exposure. Compared with Senegal, Mali showed both higher overall prevalence reflecting more intense transmission and persistent barriers to timely access to care outside study conditions.

Our findings have important public health implications. SMC is highly effective in under-fives but leaves a large untreated reservoir in older children and adults. The Dire experience highlights the rapid reversal

when SMC is interrupted[28]. Beyond diagnostics, baseline MOI and genetic diversity provide essential metrics which could be instrumental in completing the assessment of interventions such as SMC, as they capture shifts in transmission intensity and parasite population structure[29]. In addition, expanding SMC eligibility, exploring school-based delivery, and evaluating focal mass drug administration are potential strategies to address transmission beyond current control strategies. Strengths of this study include the use of sensitive molecular diagnostics, high-resolution longitudinal follow-up, and rare population-based data from both Central and Northern Mali, where security challenges have often limited research. Limitations include modest sample sizes in some strata, a cohort effect from repeated survey contacts, and enhanced access to free diagnosis and treatment for participants, which may have reduced chronic carriage compared with non-participants. Differences in cohort structure and survey-based treatment of RDT-positives between sites also shaped infection dynamics, but these contrasts created a valuable natural experiment to assess the combined effects of ecology and intervention coverage.

Conclusion

P. falciparum infections are highly prevalent in the general population of two regions of Mali. They concentrate on children from 5 years older than SMC eligibility and youth up to 24 years, but are also present in adults. The historical paradigm of the highest incidence in the youngest children is altered by SMC, and these changes should be taken into account to design additional strategies. Indeed, while vaccines are rolled out to protect the youngest children, those older are supporting persistent *Plasmodium* transmission. Strategies targeting asymptomatic carriers are likely required to further decrease Plasmodium transmission and continue progress towards elimination in seasonal settings.

Funding

This study used data produced within the MARS project (A*Midex International 2018), funded by the Excellence Initiative of Aix-Marseille University - A*MIDEX, a French "Investissements d'Avenir" programme. The funders were not involved in the design of the study, data acquisition or analysis, the decision to publish, or the writing of the manuscript.

Acknowledgements

We sincerely thank all participants, community leaders, and the residents of Safo, Torodo, Koigour, and Bourem Sidi Amar for their engagement and active role in advancing malaria control efforts. Their generosity and cooperation made this work possible. We extend special appreciation to the community health workers and health post staff for their dedication, as well as to the research assistants whose commitment was essential to the success of this study.

Conflict of interest

The authors declare no conflicts of interest.

References

1. World Health Organization. World malaria report 2024: addressing inequity in the global malaria response. Geneva: World Health Organization; 2024.

2. President's Malaria Initiative. Mali Malaria Operational Plan FY 2023. U.S. Agency for International Development; 2023.

3. SMC Alliance. Seasonal Malaria Chemoprevention Coverage in Mali [Internet]. 2021. Available from: https://www.smc-alliance.org/countries/mali-0

4. Cissé B, Ba EH, Sokhna C, et al. Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped-Wedge Cluster-Randomised Trial. Noor AM, editor. PLoS Med [Internet]. **2016** [cited 2023 May 3]; 13(11):e1002175. Available from: https://dx.plos.org/10.1371/journal.pmed.1002175

5. Kazanga B, Ba E-H, Legendre E, et al. Impact of seasonal malaria chemoprevention timing on clinical malaria incidence dynamics in the Kedougou region, Senegal. Ashton R, editor. PLOS Glob Public Health [Internet]. Public Library of Science (PLoS); **2025** [cited 2025 Jul 18]; 5(1):e0003197. Available from: https://dx.plos.org/10.1371/journal.pgph.0003197

6. Soremekun S, Conteh B, Nyassi A, et al. Household-level effects of seasonal malaria chemoprevention in the Gambia. Commun Med [Internet]. **2024** [cited 2025 Oct 21]; 4(1):97. Available from: https://www.nature.com/articles/s43856-024-00503-0

7. Legendre E, Ciré Ba E-HK, L'Ollivier C, et al. Plasmodium falciparum carriage in a population under long-term, intensive malaria control in Kedougou region, Senegal: a 1-year cohort study. The Lancet Global Health [Internet]. **2025** [cited 2025 Oct 21]; 13(11):e1935–e1945. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2214109X25002712

8. Kambou SAE, Sondo P, Kabore B, et al. Patterns of patent and sub-patent Plasmodium falciparum infections in household members of children under seasonal malaria chemoprevention coverage in the health district of Nanoro, Burkina Faso. Malar J [Internet]. **2025** [cited 2025 Oct 21]; 24(1):281. Available from: https://malariajournal.biomedcentral.com/articles/10.1186/s12936-025-05453-z

9. Coulibaly D, Travassos MA, Tolo Y, et al. Spatio-Temporal Dynamics of Asymptomatic Malaria: Bridging the Gap Between Annual Malaria Resurgences in a Sahelian Environment. The American Journal of Tropical Medicine and Hygiene [Internet]. **2017** [cited 2023 May 24]; 97(6):1761–1769. Available from: https://ajtmh.org/doi/10.4269/ajtmh.17-0074

10. Ceesay S, Kampmann M, Votborg-Novél L, et al. Plasmodium falciparum expresses fewer var genes at lower levels during asymptomatic dry season infections than clinical malaria cases. Dzikowski R, editor. PLoS Pathog [Internet]. **2025** [cited 2025 Aug 11]; 21(6):e1013210. Available from: https://dx.plos.org/10.1371/journal.ppat.1013210

11. Sanogo D, Toure M, Keita M, et al. High incidence of clinical malaria among asymptomatic Plasmodium falciparum infected children receiving SMC with sulfadoxine-pyrimethamine and amodiaquine (SP + AQ) in Koulikoro, Mali. Malar J [Internet]. **2025** [cited 2025 Aug 11]; 24(1):102. Available from: https://malariajournal.biomedcentral.com/articles/10.1186/s12936-025-05283-z

12. Collins KA, Ceesay S, Drammeh S, et al. A Cohort Study on the Duration of Plasmodium falciparum Infections During the Dry Season in The Gambia. J Infect Dis. **2022**; 226(1):128–137.

13. Brokhattingen N, Matambisso G, Da Silva C, et al. Genomic malaria surveillance of antenatal care users detects reduced transmission following elimination interventions in Mozambique. Nat Commun [Internet]. **2024** [cited 2025 Sep 11]; 15(1):2402. Available from: https://www.nature.com/articles/s41467-024-46535-x

14. Chen Y-A, Vickers EN, Aranda-Diaz A, et al. Genomic epidemiology demonstrates spatially clustered, local transmission of Plasmodium falciparum in forest-going populations in southern Lao PDR. Ferreira MU, editor. PLoS Pathog [Internet]. **2024** [cited 2025 Sep 11]; 20(9):e1012194. Available from: https://dx.plos.org/10.1371/journal.ppat.1012194

15. Sacko A, Sagara I, Berthé I, et al. Evolution of Malaria Incidence in Five Health Districts, in the Context of the Scaling Up of Seasonal Malaria Chemoprevention, 2016 to 2018, in Mali. Int J Environ Res Public Health. **2021**; 18(2):840.

16. Katile A, Sagara I, Cissoko M, et al. Spatio-Temporal Variability of Malaria Incidence in the Health District of Kati, Mali, 2015-2019. Int J Environ Res Public Health. **2022**; 19(21):14361.

17. Cissoko M, Sagara I, Sankaré MH, et al. Geo-Epidemiology of Malaria at the Health Area Level, Dire Health District, Mali, 2013–2017. IJERPH [Internet]. **2020** [cited 2023 Oct 16]; 17(11):3982. Available from: https://www.mdpi.com/1660-4601/17/11/3982

18. MalariaGEN. P. falciparum Amplicon Toolkit Protocols [Internet]. Available from: https://www.malariagen.net/resources/amplicon-sequencing-toolkit/p-falciparum-amplicontoolkit-protocols/

19. R Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2024. Available from: https://www.R-project.org/

20. Latpate R, Kshirsagar J, Kumar Gupta V, Chandra G. Advanced Sampling Methods [Internet]. Singapore: Springer Singapore; 2021 [cited 2025 Jul 18]. Available from: https://link.springer.com/10.1007/978-981-16-0622-9

21. Lumley T. Analysis of Complex Survey Samples. J Stat Soft [Internet]. Foundation for Open Access Statistic; **2004** [cited 2025 Jul 18]; 9(8). Available from: http://www.jstatsoft.org/v09/i08/

22. Murphy M, Greenhouse B. MOIRE: a software package for the estimation of allele frequencies and effective multiplicity of infection from polyallelic data. Schwartz R, editor. Bioinformatics [Internet]. **2024** [cited 2025 Sep 11]; 40(10):btae619. Available from: https://academic.oup.com/bioinformatics/article/doi/10.1093/bioinformatics/btae619/7826613

23. Chen Y, Ng P-Y, Garcia-Ruiz D, et al. Genetic surveillance reveals low but sustained malaria transmission with clonal replacement in Sao Tome and Principe. Commun Med [Internet]. **2025** [cited 2025 Sep 11]; 5(1):199. Available from: https://www.nature.com/articles/s43856-025-00905-8

24. Wood SN. Generalized additive models: an introduction with R. Second edition. Boca Raton: CRC Press/Taylor & Francis Group; 2017.

25. Lê S, Josse J, Husson F. **FactoMineR**: An*R*Package for Multivariate Analysis. J Stat Soft [Internet]. Foundation for Open Access Statistic; **2008** [cited 2025 Jul 18]; 25(1). Available from: http://www.jstatsoft.org/v25/i01/

26. Cissoko M, Magassa M, Sanogo V, et al. Stratification at the health district level for targeting malaria control interventions in Mali. Sci Rep [Internet]. **2022** [cited 2025 Oct 21]; 12(1):8271. Available from: https://www.nature.com/articles/s41598-022-11974-3

27. Katile A, Sagara I, Cissoko M, et al. Population impact of malaria control interventions in the health district of Kati, Mali. Abuaku BK, editor. PLoS ONE [Internet]. **2024** [cited 2025 Sep 9]; 19(12):e0289451. Available from: https://dx.plos.org/10.1371/journal.pone.0289451

28. Manga IA, Mhadji A, Lam A, et al. Asymptomatic carriage of Plasmodium falciparum in children no longer targeted for seasonal malaria chemoprevention and with a history of exposure to this strategy: A cross sectional study in southern Senegal. Vieira JLF, editor. PLoS ONE [Internet]. **2025** [cited 2025 Oct 21]; 20(3):e0318037. Available from: https://dx.plos.org/10.1371/journal.pone.0318037

29. Simpson SV, Nundu SS, Arima H, et al. The diversity of Plasmodium falciparum isolates from asymptomatic and symptomatic school-age children in Kinshasa Province, Democratic Republic of Congo. Malar J. **2023**; 22(1):102.

Author contributions

JL, IS, JG, and E-HKCB designed the study, with contributions from SR, MCi, MKBD and AD. JL, IS, E-HKCB, JG, MKBD, MCi, AK, EL, AC, and CL'O designed the methodological approach, study procedures, and tools. AD, ODAP, MC, PK, BKam, MBK, PK, AZ collected data and samples. CL'O, MM designed and conducted the PCR assays. JL and BKa designed the statistical analysis plan and assessed and verified the data. BK conducted the analysis with support from EBB on eMOI analysis. JL, BKa and EBB interpreted the findings. BK and EBB created the figures. BK wrote the first draft of the manuscript. All authors reviewed and revised the manuscript and approved this version of the Article for publication.

Data availability

Data are available on request from the corresponding author.